Skip to main navigation Skip to search Skip to main content

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

  • Paula I. Gonzalez-ericsson
  • , Julia D. Wulfkhule
  • , Rosa I. Gallagher
  • , Xiaopeng Sun
  • , Margaret L. Axelrod
  • , Quanhu Sheng
  • , Na Luo
  • , Henry Gomez
  • , Violeta Sanchez
  • , Melinda Sanders
  • , Lajos Pusztai
  • , Emanuel Petricoin
  • , Kim R.m. Blenman
  • , David A Potter
  • , Justin M. Balko

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)5299-5306
JournalClinical Cancer Research
Volume27
Issue number19
DOIs
StatePublished - Oct 1 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this